Sanxin Medical announced on July 16. Recently, artificial vascular products independently developed by Jiangxi Colevipid Biotechnology Co., Ltd., the company's holding subsidiary, obtained approval from the Medical Device Technical Evaluation Center of the State Drug Administration and entered a special review procedure for innovative medical devices. Innovative medical device products that have entered the special examination procedure for innovative medical devices can enjoy priority processing rights at the time of registration and application. Drug supervisory and administrative departments and relevant technical agencies will conduct reviews and approvals on the premise that standards are not lowered or procedures are not reduced in accordance with the principles of early intervention, dedicated personnel responsibility, and scientific review.

Sanxin Medical announced on July 16. Recently, artificial vascular products independently developed by Jiangxi Colevipid Biotechnology Co., Ltd., the company's holding subsidiary, obtained approval from the Medical Device Technical Evaluation Center of the State Drug Administration and entered a special review procedure for innovative medical devices. Innovative medical device products that have entered the special examination procedure for innovative medical devices can enjoy priority processing rights at the time of registration and application. Drug supervisory and administrative departments and relevant technical agencies will conduct reviews and approvals on the premise that standards are not lowered or procedures are not reduced in accordance with the principles of early intervention, dedicated personnel responsibility, and scientific review.